Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
N/ANon-phased studies
4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

completed250%
recruiting125%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions

NCT03371641
completednot_applicable

Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus

NCT01251744
unknownnot_applicable

Assessing Neurodevelopment in Congenital Heart Disease.

NCT02996630
completednot_applicable

IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE

NCT01865435

Clinical Trials (4)

Showing 4 of 4 trials
NCT03371641Not Applicable

In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions

Recruiting
NCT01251744Not Applicable

Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus

Completed
NCT02996630Not Applicable

Assessing Neurodevelopment in Congenital Heart Disease.

Unknown
NCT01865435Not Applicable

IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4